Walder Wyss Advises Allegria Therapeutics on USD 5.1 Million Seed Extension

"Walder Wyss advised Basel-based Allegria Therapeutics on a USD 5.1 million seed extension led by ALK Abelló with support from HighLight Capital, the Lichtsteiner Foundation and Forty51 Ventures. Proceeds will advance Allegria’s lead program toward preclinical and first clinical candidate nomination and support discovery-stage programs."

Walder Wyss advised Allegria Therapeutics, a Basel-based biotech developing therapies for mast cell-mediated diseases, in connection with its USD 5.1 million seed extension funding round. ALK Abelló led the financing, with support from HighLight Capital, the Lichtsteiner Foundation and co-founding investor Forty51 Ventures. The funds raised in this round will be used to advance Allegria’s lead program toward preclinical and first clinical candidate nomination and to support the development of discovery-stage programs. Walder Wyss represented client Allegria Therapeutics with a team composed by: partner Alexander Gutmans, managing associate Karina Tschon and associate Oerjan Wickart — all specialising in corporate/M&A and venture capital.

Walder Wyss Advises Allegria Therapeutics on USD 5.1 Million Seed Extension

Read the full story